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Abstract
Calcitonin gene-related peptide (CGRP) plays an important role in peripheral and central sensitization. CGRP also is
a key molecule in the spino-parabrachial-amygdaloid pain pathway. Blockade of CGRP1 receptors in the spinal cord
or in the amygdala has antinociceptive effects in different pain models. Here we studied the electrophysiological
mechanisms of behavioral effects of CGRP in the amygdala in normal animals without tissue injury.
Whole-cell patch-clamp recordings of neurons in the latero-capsular division of the central nucleus of the amyg-
dala (CeLC) in rat brain slices showed that CGRP (100 nM) increased excitatory postsynaptic currents (EPSCs) at the
parabrachio-amygdaloid (PB-CeLC) synapse, the exclusive source of CGRP in the amygdala. Consistent with a post-
synaptic mechanism of action, CGRP increased amplitude, but not frequency, of miniature EPSCs and did not affect
paired-pulse facilitation. CGRP also increased neuronal excitability. CGRP-induced synaptic facilitation was reversed
by an NMDA receptor antagonist (AP5, 50 μM) or a PKA inhibitor (KT5720, 1 μM), but not by a PKC inhibitor
(GF109203X, 1 μM). Stereotaxic administration of CGRP (10 μM, concentration in microdialysis probe) into the CeLC
by microdialysis in awake rats increased audible and ultrasonic vocalizations and decreased hindlimb withdrawal
thresholds. Behavioral effects of CGRP were largely blocked by KT5720 (100 μM) but not by GF109203X (100 μM).
The results show that CGRP in the amygdala exacerbates nocifensive and affective behavioral responses in normal
animals through PKA- and NMDA receptor-dependent postsynaptic facilitation. Thus, increased CGRP levels in the
amygdala might trigger pain in the absence of tissue injury.
Introduction
Calcitonin gene-related peptide (CGRP) is a 37 amino
acid peptide that binds to G-protein-coupled receptors,
including CGRP1, which couple positively to adenylyl
cyclase, cyclic AMP formation and protein kinase A
(PKA) activation [1-4]. CGRP has emerged as an impor-
tant molecule at different levels of the pain neuraxis [5].
Particularly high levels of CGRP binding sites [1,4,6,7]
and proteins required for functional CGRP1 receptors
[8,9] have been described in the superficial spinal dorsal
horn and in the central nucleus of the amygdala (CeA),
where also CGRP containing fibers terminate
[4,7,10-13].
Work from our group and others showed that pain-
related plasticity in the latero-capsular division of the
CeA (CeLC) contributes critically to the emotional-
affective dimension of pain [14,15]. The CeLC is essen-
tially delineated by CGRP immunoreactive fibers that
arise from the external lateral parabrachial area (PB)
[12,13,16,17]. The PB projection to the CeLC provides
purely nociceptive input to the amygdala as part of the
spino-parabrachio-amygdaloid pain pathway that origi-
nates in lamina I [18-20]. Lamina I neurons projecting
to the PB receive direct peptidergic afferent input [19],
including from CGRP containing fibers [7].
Consistent with an important role of CGRP on the
input and output sides of the spino-parabrachio-amyg-
daloid pain pathway, blockade of CGRP1 receptors in
the spinal dorsal horn [21] or the amygdala [22] inhib-
ited pain-related central sensitization of CeLC neurons
and nocifensive and affective behaviors. Central sensiti-
zation of CeLC neurons involves synaptic plasticity at
the PB-CeLC synapse and increased neuronal excitability
[14,15] in models of arthritic [23], visceral [24] and
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any medium, provided the original work is properly cited.neuropathic [25] pain. Arthritis pain-related plasticity in
the CeLC depends on increased function of postsynaptic
NR1/NR2B NMDA receptors through PKA-dependent
NR1 phosphorylation [26-28] and endogenous activation
of CGRP1 [22] and CRF1 [29,30] receptors. Mechanisms
of pain-related PKA activation in the CeLC remained to
be determined, but both CGRP1 and CRF1 receptors
couple to PKA activation.
Central sensitization and plasticity in the CeLC corre-
late with increased pain behavior because pharmacologic
deactivation of the CeLC with antagonists for group I
metabotropic glutamate receptors [31,32], CGRP1 [22]
and CRF1 [30] receptors, GABA-A agonist [33], and
inhibitors of PKA, but not PKC, and ERK [34,35]
decreased nocifensive and affective pain behaviors in dif-
ferent pain models. Conversely, in normal animals ERK
activation in the CeLC [35], corticosterone delivery to
the CeA [36] and block of GABA-A receptors in the
CeA [33] increased peripheral hypersensitivity, although
it was not clear if these effects correlated positively with
amygdala activity.
Neuronal effects of CGRP in the amygdala remain to
be determined. Mechanisms of CGRP actions in general
are not well understood. In the spinal cord, CGRP
increased responses of dorsal horn neurons [37-40] and
nocifensive behavior [40-43] by increasing synaptic
transmission and neuronal excitability [44,45]. Activa-
tion of PKA and PKC, modulation of AMPA and
NMDA receptor function, and interactions with sub-
stance P have been implicated in the spinal actions of
CGRP [5]. The goal of the present study was to deter-
mine synaptic and cellular effects of CGRP in the CeLC,
underlying mechanisms and behavioral consequences in
naïve animals without tissue injury.
Methods
Male Sprague Dawley rats (150-350 g) were housed in a
temperature controlled room and maintained on a 12 h
day/night cycle. Water and food were available ad libi-
tum. All experimental procedures were approved by the
Institutional Animal Care and Use Committee (IACUC)
at the University of Texas Medical Branch (UTMB) and
conform to the guidelines of the International Associa-
tion for the Study of Pain (IASP) and of the National
Institutes of Health (NIH).
Electrophysiology: patch-clamp recording
Coronal brain slices (300-500 μm) containing the CeLC
were obtained from normal untreated rats (150-250 g)
as previously described [22,30]. Rats were decapitated
without the use of anesthesia to avoid chemical contam-
ination of the tissue. A single brain slice was transferred
to the recording chamber and submerged in artificial
cerebrospinal fluid (ACSF; 31 ± 1°C), which superfused
the slice at ~2 ml/min. ACSF contained (in mM) NaCl
117, KCl 4.7, NaH2PO4 1.2, CaCl2 2.5, MgCl2 1.2,
NaHCO3 25, and glucose 11. The ACSF was oxygenated
and equilibrated to pH 7.4 with a mixture of 95% O2/5%
CO2. Only one or two brain slices per animal were used,
one neuron was recorded in each slice, and a fresh slice
was used for each new experimental protocol. Numbers
in the manuscript refer to the number of neurons tested
for each parameter.
Whole-cell patch-clamp recordings were obtained
from CeLC neurons using the “blind” patch technique
as previously described [22,30]. The boundaries of the
different amygdalar nuclei are easily discerned under
light microscopy (see Figure 1 in [30]). Recording pip-
ettes (3-5 MΩ tip resistance) were made from borosili-
cate glass (1.5 mm and 1.12 mm, outer and inner
diameter, respectively; Drummond, Broomall, PA) using
a Flaming-Brown micropipette puller (P-80/PC, Sutter
Instrument Co., Novato, CA). Electrodes were filled
with intracellular solution containing (in mM): 122 K-
gluconate, 5 NaCl, 0.3 CaCl2,2M g C l 2,1E G T A ,1 0
HEPES, 5 Na2-ATP, and 0.4 Na3-GTP; pH was adjusted
to 7.2-7.3 with KOH and osmolarity to 280 mOsm/kg
with sucrose. Data acquisition and analysis of voltage
and current signals were done using a dual 4-pole Bessel
filter (Warner Instr.), low-noise Digidata 1322 interface
(Axon Instr.), Axoclamp-2B amplifier (Axon Instr.), Pen-
tium PC, and pClamp9 software (Axon Instr.). Signals
were low-pass filtered at 1 kHz and digitized at 5 kHz.
Headstage voltage was monitored continuously on an
oscilloscope to ensure precise performance of the ampli-
fier. High (> 2 GΩ) seal and low (< 20 MΩ) series resis-
tances were checked throughout the experiment (using
pClamp9 membrane test function) to ensure high-qual-
ity recordings. If series resistance (monitored with
pClamp9 software, Axon Instr.) changed more than
10%, the neuron was discarded. Neurons were recorded
at -60 mV.
Using concentric bipolar stimulating electrodes (SNE-
100, Kopf Instr.; 22 kW), monosynaptic EPSCs were
evoked in CeLC neurons by focal electrical stimulation
(Grass S88 stimulator) of inputs from the PB. For stimu-
lation of the PB-CeLC synapse, the electrode was posi-
tioned under microscopic control on the afferent fiber
tract from the lateral PB, which runs dorsomedial to the
CeA and ventral to but outside of the caudate-putamen
[22,30]. In the vicinity of this tract, no other afferents to
the CeA have been described [17,46]. Electrical stimuli
(150 μs square-wave pulses) were delivered at low fre-
quencies (< 0.25 Hz). Input-output functions were
obtained by increasing the stimulus intensity in 100 μA
steps. For evaluation of a drug effect on synaptically
evoked responses, the stimulus intensity was adjusted to
75-80% of the intensity required for orthodromic spike
generation.
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synaptic stimuli of equal intensity were applied at vary-
ing intervals and the resulting EPSCs were recorded.
Peak amplitudes of the initial EPSC (EPSC1) and the
second EPSC (EPSC2) were measured as the difference
between the current level before the stimulus artifact
and the peak of the EPSC. PPR was calculated as the
ratio of EPSC2 over EPSC1 and expressed in %. Any
alterations in PPR, a measure of short-term synaptic
plasticity, suggest a presynaptic site of action [22,30].
Miniature EPSCs (mEPSCs) were recorded in TTX 1
μM as described previously [22,30]. A fixed length of
traces (5 min) was analyzed for frequency and amplitude
distributions using MiniAnalysis program 5.3 (Synapto-
soft, Decatur, GA). The root mean square (RMS) of the
background noise was computed for each set of data.
The detection threshold for an event was set to three to
four times the RMS value. Peaks were detected automa-
tically, but each detected event was then visually
inspected to prevent the inclusion of false data.
Drugs (see below) were applied by gravity-driven
superfusion of the brain slice in the ACSF (~2 ml/min).
Solution flow into the recording chamber (1 ml volume)
was controlled with a three-way stopcock.
Behavioral tests
Adult male Sprague-Dawley rats (250-350 g) were used
in all experiments.
Spinal reflexes
Thresholds of hindlimb withdrawal reflexes evoked by
mechanical stimulation of the knee joint were measured
as described previously [47]. Mechanical stimuli of con-
tinuously increasing intensity were applied to the knee
joint by means of a forceps equipped with a force trans-
ducer, whose calibrated output was amplified and dis-
played in grams on a liquid crystal display screen.
Withdrawal threshold was defined as the minimum sti-
mulus intensity that evoked a withdrawal reflex.
Vocalizations
Audible and ultrasonic vocalizations were recorded and
analyzed as described previously [31,47,48]. The experi-
mental setup (U.S. Patent 7,213,538) included a custom-
designed recording chamber, a condenser microphone
(audible range, 20 Hz to 16 kHz) connected to a pream-
plifier, an ultrasound detector (25 ± 4 kHz), filter and
amplifier (UltraVox 4-channel system; Noldus Informa-
tion Technology, Leesburg, VA), and data acquisition
software (UltraVox 2.0; Noldus Information Technol-
ogy), which automatically monitored the occurrence of
vocalizations within user-defined frequencies and
recorded number and duration of digitized events (voca-
lizations). Vocalizations in the audible and ultrasonic
ranges were recorded simultaneously but with different
microphones (condenser microphone and bat detector,
respectively) connected to separate channels of the
Figure 1 CGRP enhances synaptic transmission in the CeLC in
slices from normal animals. (A) Monosynaptic EPSCs evoked at
the PB-CeLC synapse with increasing stimulus intensities before and
during CGRP (100 nM, 12 min). Individual traces are the average of
10 EPSCs. (B) CGRP (100 nM, 10-14 min) increased input-output
function of the PB-CeLC synapse significantly (n = 10, P < 0.0001,
F1,198 = 67.97, two-way ANOVA). Input-output curves were
generated by plotting peak EPSC amplitude (pA) as a function of
afferent fiber volley stimulus intensity (μA). (C) Synaptic facilitation
by CGRP was blocked by co-administration of a CGRP1 receptor
antagonist (CGRP8-37, 1 μM). Individual traces are the average of 8-
10 EPSCs. (D) Cumulative concentration-response relationship of
CGRP effects on synaptic transmission at the PB-CeLC synapse (n =
15). Peak amplitudes of monosynaptic EPSCs were averaged for
each concentration of CGRP and expressed as percent of predrug
control (set to 100%). Concentration-response curve was obtained
by non-linear regression analysis using the formula y = A+(B-A)/[1
+(10
C/10
X)
D], where A is the bottom plateau, B top plateau, C = log
(IC50), and D is the slope coefficient (GraphPad Prism software).
CGRP8-37 (1 μM, n = 6) blocked the effect of CGRP (100 nM). CeLC
neurons were recorded at -60 mV in slices from naïve untreated
animals. Symbols and error bars represent mean ± SEM. *, **, *** P
< 0.05-0.001 (Bonferroni posttests).
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suppress non-relevant audible sounds (background
noise) and to ignore ultrasounds outside the defined fre-
quency range. The chamber also had an opening for
drug administration through the microdialysis probe
inserted into the implanted guide cannula (see below).
Animals were placed in the recording chamber for accli-
mation 1 h before the vocalization measurements.
Brief (15 s) innocuous (500 g/30 mm
2) and noxious
(2000 g/30 mm
2) mechanical stimuli were applied to the
knee, using a calibrated forceps (see above). Stimulus
intensities of 100-500 g/30 mm
2 applied to the knee and
other deep tissue are considered innocuous because they
do not evoke hindlimb withdrawal reflexes in awake rats
and are not felt to be painful when tested on the experi-
menters. Pressure stimuli >1500 g/30 mm
2 are noxious
because they evoke hindlimb withdrawal reflexes in
awake rats and are distinctly painful when applied to
the experimenters [47]. The total duration of vocaliza-
tions (arithmetic sum of the duration of individual
events) was recorded for 1 min, starting with the onset
of the mechanical stimulus.
Drug application by microdialysis in awake animals
As described in detail previously [22,30,31,47], a guide
cannula was implanted stereotaxically the day before
behavioral measurements, using a stereotaxic apparatus
(David Kopf Instr.). The animal was anesthetized with
pentobarbital sodium (Nembutal®, 50 mg/kg, i.p.) and a
small unilateral craniotomy was performed at the sutura
frontoparietalis level. The guide cannula was implanted
on the dorsal margin of the CeLC, using the following
coordinates (in mm): CeLC, 2.0 caudal to bregma, 4.0 lat-
eral to midline, depth 7.0. The cannula was fixed to the
skull with dental acrylic (Plastics One, Roanoke, VA).
Antibiotic ointment was applied to the exposed tissue to
prevent infection. On the day of the experiment, a micro-
dialysis probe (CMA12; CMA/Microdialysis Inc., North
Chelmsford, MA; 20 kD cut-off, membrane length 2
mm) was inserted through the guide cannula so that the
probe protruded beyond the tip of the guide cannula by 2
mm. The probe was connected to a Harvard infusion
pump and perfused with ACSF (oxygenated and equili-
brated to pH = 7.4). Before each drug application, ACSF
was pumped through the fiber for at least 1 h to establish
equilibrium in the tissue. Drugs were dissolved in ACSF
on the day of the experiment at a concentration 100-fold
that predicted to be needed based on data from our pre-
vious microdialysis and in vitro studies and data in the
literature [5,22,30,45]. Drug concentration in the tissue is
at least 100 times lower than in the microdialysis probe
as a result of the concentration gradient across the dialy-
sis membrane and diffusion in the tissue [22,30]. Num-
bers in the manuscript refer to drug concentrations in
the microdialysis fiber.
Histological verification of drug administration sites
At the end of a behavioral experiment, the animal was
sacrificed by decapitation using a guillotine (Harvard
Apparatus Decapitator). This method of sacrifice is con-
sistent with the recommendations of the Panel on
Euthanasia of the American Veterinary Medical Associa-
tion and approved by the Institutional Animal Care and
Use Committee (IACUC). The brain was removed and
submerged in 10% formalin. Tissues were stored in 20%
s u c r o s eb e f o r et h e yw e r ef r o z e ns e c t i o n e da t5 0μm.
Sections were stained with Neutral Red, mounted on
gel-coated slides, and coverslipped. Positions of the
microdialysis fibers were identified under the micro-
s c o p e[ 3 0 ]a n dp l o t t e do ns t a n d a r dd i a g r a m s[ f r o m
[49]].
Drugs
Rat calcitonin gene-related peptide (CGRP)a n d
CGRP8-37 (CGRP1 receptor antagonist) were pur-
chased from Bachem, Torrance, CA. The following com-
pounds were purchased from Tocris Bioscience
(Ellisville, MO): (9R,10S,12S)-2,3,9,10,11,12-hexahydro-
10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo
[1,2,3-fg:3’,2’,1’-kl]pyrrolo [3,4-i][1,6]benzodiazocine-10-
carboxylic acid, hexyl ester (KT5720; membrane-perme-
able potent and selective PKA inhibitor [26,50]); 2- [1-
(3-dimethylaminopropyl)indol-3-yl]-3-(indol-3-yl) malei-
mide (GF109203x; membrane-permeable potent and
selective PKC inhibitor [51]); DL-2-amino-5-phospho-
nopentanoic acid (AP5; NMDA receptor antagonist).
Drugs were dissolved in ACSF on the day of the experi-
ment. ACSF served as vehicle control in all experiments.
Statistical analysis
All averaged values are given as the mean ± SEM. Statis-
tical significance was accepted at the level P < 0.05.
GraphPad Prism 3.0 software (Graph-Pad Software, San
Diego, CA) was used for all statistical analysis. For mul-
tiple comparisons, one-way ANOVA or two-way
ANOVA was used with Bonferroni posttests to compare
selected pairs of data). Paired student t-test was used to
compare two sets of data that follow Gaussian distribu-
tion and have similar variances. Kolmogorov-Smirnov
test was used for cumulative distribution analysis of
mEPSCs (MiniAnalysis program 5.3 (Synaptosoft Inc.,
Decatur, GA). Concentration-response curves were
obtained by non-linear regression analysis using the for-
mula y = A+(B-A)/[1+(10
C/10
X)
D], where A is the bot-
tom plateau, B top plateau, C =l o g ( I C 50), and D is the
slope coefficient (GraphPad Prism software).
Results
Our previous studies showed that neurons in the latero-
capsular part of the central nucleus of the amygdala
(CeLC) develop synaptic plasticity and increased respon-
siveness in a model of arthritic pain [14,15] through a
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activation in the amygdala [22]. However, the effect of
CGRP itself on synaptic transmission and neuronal
excitability in the amygdala is not known and was deter-
mined in this study.
Facilitation of synaptic transmission by CGRP
Whole-cell voltage-clamp recordings of CeLC neurons
were made in brain slices from naïve untreated rats.
Superfusion of the slices with CGRP significantly
enhanced synaptic transmission, mimicking synaptic
plasticity observed in the arthritic pain model. Monosy-
naptic EPSCs of progressively larger amplitudes were
evoked by electrical synaptic stimulation of presumed
PB afferents [30] with increasing intensities. Input-out-
put relationships were obtained by measuring EPSC
peak amplitude (pA) as a function of afferent fiber volley
stimulus intensity (μA) for each neuron (Figure 1A).
Baseline EPSCs are mediated by non-NMDA receptors
as they persist in the presence of NMDA receptor
blockade (see AP5 data below and our previous studies
[26]). CGRP enhanced the input-output function of the
PB-CeLC synapse significantly as evidenced by the stee-
per slope and upward shift at higher stimulus intensities
(Figure 1B; n = 10, P < 0.0001, F1,198 = 67.97, two-way
ANOVA). The facilitatory effects of CGRP were concen-
tration-dependent (apparent EC50 = 28.3 nM; Figure 1D;
n = 15, P < 0.001, F = 9.681, one-way ANOVA). A
CGRP1 receptor antagonist (CGRP8-37, 1 μM) blocked
the facilitatory effects of CGRP (100 nM) significantly (n
= 6; P < 0.01, one-way ANOVA with Bonferroni postt-
est; see individual example in Figure 1C and averaged
data in Figure 1D). CGRP1 receptor antagonists have no
effect on baseline synaptic transmission in CeLC neu-
rons [22]. These data show the presence of functional
CGRP receptors in the CeLC under normal conditions.
Post- rather than pre-synaptic site of action
To determine whether CGRP acts pre- or post-synapti-
cally in the CeLC we used a number of well-established
electrophysiological methods, including paired-pulse
facilitation (PPR) and miniature EPSC (mEPSC) analysis.
These parameters were measured before and during
application of CGRP. PPR was calculated as the ratio of
the second and the first of two consecutive EPSCs
evoked at the PB-CeLC synapse by two electrical stimuli
of equal intensity at increasing inter-stimulus intervals
(Figure 2A, individual example; Figure 2B, summarized
data). CGRP (100 nM, 12 min) had no significant effect
on PPR at various inter-stimulus intervals (n = 12, P >
0.05, F1,110 = 0.24, two-way ANOVA), arguing against a
presynaptic action. The analysis of amplitude and fre-
quency distribution of mEPSCs in the presence of TTX
can be used to determine pre- versus post-synaptic
mechanisms. Presynaptic changes at the transmitter
release site affect mEPSC frequency, whereas changes at
the postsynaptic membrane alter mEPSC amplitude
(quantal size) [22,30,52]. CGRP (100 nM, 12 min)
increased the amplitude, but not frequency, of mEPSCs
recorded in CeLC neurons in the presence of TTX (1
μM) (Figure 2C; n = 4). CGRP caused a significant shift
o ft h ec u m u l a t i v em E P S Ca m p l i t u d ed i s t r i b u t i o n
towards larger amplitudes (P < 0.001, Kolmogorov-Smir-
nov test; Figure 2D) and increased the mean mEPSC
amplitude significantly (P < 0.05, paired t-test; Figure
2D, bar histogram). CGRP had no effect on the fre-
quency of mEPSCs (see cumulative inter-event interval
distribution, P > 0.05, Kolmogorov-Smirnov test; mean
mEPSC frequency, P > 0.05, paired t-test; Figure 2D).
The results of PPR and mEPSC analysis are consistent
with a postsynaptic site of action of CGRP.
To determine the effect of CGRP on neuronal excit-
ability, action potentials were evoked in current-clamp
mode by direct intracellular current injections of
increasing magnitude through the patch electrode.
Input-output functions of neuronal excitability were
obtained by averaging the frequency of action potentials
evoked at each current intensity. Neurons were regular-
spiking and showed no accommodation of action poten-
tial firing in response to sustained depolarization, which
is characteristic of Type A projection neurons [53,54].
CGRP significantly increased the input-output function
of CeLC neurons (Figure 2E, F, n = 11, P < 0.0001,
F1,156 = 82.12, two-way ANOVA).
Inhibition of PKA, but not PKC, blocks CGRP-induced
synaptic facilitation
PKA, but not PKC, plays a critical role in pain-related
plasticity in the CeLC [34]. The mechanism of PKA acti-
vation is not clear yet, but CGRP receptors couple to
cAMP formation and PKA activation [1-4]. Therefore,
we tested the hypothesis that CGRP-induced synaptic
facilitation depends on PKA. A selective PKA inhibitor
(KT5720, 1 μM) decreased synaptic facilitation by CGRP
significantly (Figure 3A, B, n = 7, P < 0.05, paired t-test
compared to predrug). The effect of KT5720 was rever-
sible. In contrast, a selective PKC inhibitor (GF109203x,
1 μM) had no significant effect on CGRP-induced
synaptic facilitation (Figure 3C, D, n = 6, P > 0.05,
paired t-test).
CGRP-induced synaptic facilitation involves NMDA
receptors
PKA-dependent increase of NMDA receptor function is
an important mechanism of arthritis pain-related synap-
tic plasticity in the CeLC [26]. Here we sought to deter-
mine if CGRP-induced synaptic facilitation also depends
on NMDA receptors. Baseline synaptic transmission at
the PB-CeLC synapse is mediated by non-NMDA recep-
tors [26]. In the presence of an NMDA receptor antago-
nist (AP5, 50 μM) CGPR had no significant effect on
synaptic transmission (Figure 4A, B, n = 4, P > 0.05,
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Page 5 of 14Figure 2 Post- rather than pre-synaptic effects of CGRP. (A, B) Paired-pulse ratio (PPR), a measure of presynaptic mechanisms, was not
affected by CGRP (100 nM, 12 min). (A) Current traces (average of 8-10 EPSCs) recorded in an individual CeLC. Inter-stimulus interval, 50 ms. (B)
CGRP had no significant effect on PPR in the sample of neurons (n = 12, P > 0.05, F1,110 = 0.24, two-way ANOVA). (C) Original current traces of
mEPSCs recorded in an individual CeLC neuron in the presence of TTX (1 μM). CGRP (100 nM, 12 min) increased amplitude, but not frequency,
of mEPSCs. (D) Cumulative distribution analysis of mEPSCs amplitude and frequency. CGRP (100 nM, 12 min) caused a significant shift toward
larger amplitudes (n = 4, P < 0.001, Kolmogorov-Smirnov test) but had no effect on inter-event interval distribution. CGRP selectively increased
mean mEPSC amplitude (P < 0.05, paired t-test) but not mean frequency (n = 4; see bar histograms showing data normalized to predrug
control). (E) Number of action potentials evoked in a CeLC neuron by direct intracellular injections of depolarizing current pulses (500 ms) of
increasing magnitude (lower traces) increased during superfusion of CGRP (100 nM, 12 min; upper traces). (F) CGRP increased input-output
functions significantly (n = 11, P < 0.0001, F1,156 = 82.12, two-way ANOVA). Recordings were made in slices from naïve (untreated) animals.
Neurons were recorded at -60 mV. Symbols and error bars represent mean ± SEM. * P < 0.05 (paired-test).
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Page 6 of 14Figure 3 Inhibition of PKA, but not PKC, blocks synaptic effects of CGRP. (A) Original recordings of monosynaptic EPSCs (average of 10
EPSCs) evoked at the PB-CeLC synapse. Facilitatory effects of CGRP (100 nM) were blocked by co-administration of a PKA inhibitor (KT5720, 1
μM). (B) Summary of time course data for the sample of CeLC neurons (n = 7) show the inhibitory effects of KT5720 were reversible after
washout. Peak amplitudes of EPSCs recorded during drug application were expressed as percent of predrug control values (set to 100%). (C)
Individual traces (average of 8-10) of monosynaptic EPSCs show that the facilitatory effects of CGRP (100 nM) were not blocked by co-
administration of a PKC inhibitor (GF109203x, 1 μM). (D) Summary of time course data for the sample of CeLC neurons show that the effects of
CGRP did not desensitize during drug application for 30 min (n = 6; display as in (B)). Symbols and error bars represent mean ± SEM. * P < 0.05;
n.s. (not significant), P > 0.05 (paired t-test, comparing the last measurement before and during application of cAMP-RP or KT5720). Statistical
analysis was performed on raw data.
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induced synaptic facilitation significantly (Figure 4C, D,
n = 4, P < 0.01, one-way ANOVA with Bonferroni
posttest). The data suggest that synaptic facilitation by
CGRP depends on NMDA receptors rendered functional
at resting membrane potentials as previously described
in the arthritis pain model [26].
Inhibition of PKA, but not PKC, blocks CGRP-induced
behavioral responses
The behavioral consequences of pain-related changes in
the CeLC include increased vocalizations in the audible
and ultrasonic ranges and increased spinal reflexes
[14,22,30,31,34], which are inhibited by blockade of
CGRP1 receptors in the CeLC [22]. Here we determined
the effects of CGRP administration into the CeLC on
spinally (hindlimb withdrawal reflexes) and supraspinally
(vocalizations) organized behaviors of normal naïve
animals.
Vocalizations
Audible vocalizations evoked by an aversive stimulus
represent a supraspinally organized nocifensive response
whereas ultrasonic vocalizations reflect the affective
state of the animal [47,48]. Vocalizations were measured
using a computerized analysis system as described pre-
viously [22,31,47] (see Methods). Vocalizations in the
audible (20 Hz to 16 kHz; Figure 5A) and ultrasonic (25
± 4 kHz; Figure 5B) ranges were evoked by brief innocu-
ous (500 g/30 mm
2)a n dn o x i o u s( 2 0 0 0g / 3 0m m
2)s t i -
mulation of the knee. Vocalizations were recorded for a
period of 1 min starting with the onset of the stimulus.
No apparently different effects were found in this study
on vocalizations during stimulation and vocalization
afterdischarges [31]. Therefore, the total duration (sum
of individual vocalization events) is shown. Rats did not
vocalize spontaneously in a control period of 5-10 min
before stimulation. Administration of CGRP (10 μM,
concentration in the microdialysis probe; 15 min) into
the CeLC increased the duration of audible (Figure 5A)
and ultrasonic (Figure 5B) vocalizations significantly (n
= 5 in each group, P < 0.05-0.01 compared to predrug
controls, Bonferroni posttests). CGRP increased vocali-
zations to innocuous and noxious stimuli, which is con-
sistent with the presence of allodynia and hyperalgesia,
respectively [48]. Predrug baseline measurements were
made during administration of ACSF through the
microdialysis probe as vehicle control.
Co-administration of a PKA inhibitor (KT5720, 100
μM, concentration in microdialysis probe) reversed the
effects of CGRP on audible (Figure 5A) and ultrasonic
(Figure 5B) vocalizations significantly (n = 5, P < 0.05
compared to predrug baseline, Bonferroni posttests). In
contrast, co-administration of a PKC inhibitor
(GF109203x, 100 μM) had no significant effect on
CGRP-evoked vocalizations (Figure 5A, B, n = 5). In a
separate group of rats the effect of CGRP was reversed
by CGRP8-37 (100 μM, concentration in the microdialy-
sis probe; n = 4, P < 0.05 compared to CGRP, Bonfer-
roni posttests; data not shown).
Spinal reflexes
Thresholds for hindlimb withdrawal reflexes were deter-
m i n e db yc o m p r e s s i n gt h ek n e ej o i n tw i t hg r a d u a l l y
increasing stimulus intensities using a calibrated forceps
whose output was displayed on an LCD screen (see
Methods). Application of CGRP (10 μM, 15-20 min)
into the CeLC decreased reflex thresholds significantly
(Figure 5C, n = 5 in each group, P < 0.05-0.01, com-
pared to predrug baseline, Bonferroni posttests),
Figure 4 NMDA receptor antagonist blocks CGRP effects. (A)
Original recordings of monosynaptic EPSCs (average of 8-10 EPSCs)
evoked at the PB-CeLC synapse in the presence of AP5 (50 μM).
CGRP (100 nM) had no effect. (B) Normalized data for the sample of
CeLC neurons (n = 4). Peak amplitudes of EPSCs recorded during
drug application were expressed as percent of predrug control
values (set to 100%). (C) Individual traces (average of 8-10) of
monosynaptic EPSCs show that the facilitatory effects of CGRP (100
nM) were blocked by co-administration of AP5 (50 μM). (D)
Normalized data for the sample of CeLC neurons (n = 4; display as
in (B)). Bar histograms show mean ± SEM. n.s. (not significant), P >
0.05 (paired t-test), ** P < 0.01 (ANOVA with Bonferroni posttests).
Statistical analysis was performed on raw data.
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Page 8 of 14Figure 5 Inhibition of PKA, but not PKC, blocks behavioral effects of CGRP. Vocalizations and hindlimb withdrawal thresholds were
measured in awake rats before and during application of CGRP into the CeLC. Audible (A) and ultrasonic (B) vocalizations in response to brief
(15 s) compression of the knee with innocuous (500 g/30 mm
2) or noxious (2000 g/30 mm
2) intensity (see Methods) were measured for 1 min
starting with the onset of the stimulus (see Methods). No vocalizations were detected in a control period of 5-10 min before stimulation.
Administration of CGRP (10 μM, concentration in microdialysis probe; 15 min) into the CeLC evoked or increased vocalizations of naïve rats (n =
5 in each group). Co-administration of a PKA inhibitor (KT5720, 100 μM, n = 5) reversed the effects of CGRP; a PKC inhibitor (GF109203x, 100 μM,
n = 5) had no significant effect. (C) Thresholds of hindlimb withdrawal reflexes measured by compressing the knee with a calibrated forceps
(see Methods) were decreased by CGRP administered into the CeLC (10 μM, concentration in microdialysis probe; 15-20 min; n = 5 in each
group). Co-administration of KT5720 (100 μM, n = 5) partially reversed the effects of CGRP. GF109203x (100 μM, n = 5) had no significant effect.
Bar histograms and error bars represent mean ± SE. * P < 0.05, ** P < 0.01 (ANOVA with Bonferroni posttests, compared to predrug control).
# P
< 0.05 (ANOVA with Bonferroni posttests, compared to CGRP).
Han et al. Molecular Pain 2010, 6:10
http://www.molecularpain.com/content/6/1/10
Page 9 of 14reflecting allodynic pain behavior. Co-administration of
a PKA inhibitor (KT5720, 100 μM) reversed the effects
of CGRP on (Figure 5C, n = 5, P < 0.05 compared to
predrug baseline, Bonferroni posttests), whereas a PKC
inhibitor (GF109203x, 100 μM) had no significant effect
(Figure 5C, n = 5). The effect of CGRP was reversed by
CGRP8-37 (100 μM, concentration in the microdialysis
probe; n = 4, P < 0.05 compared to CGRP, Bonferroni
posttests; data not shown).
Histology and placement controls
Drug application sites into the CeLC were verified histo-
logically. Figure 6 shows the position of the tips of the
microdialysis probes. Applications of CGRP (100 nM, 15-
20 min) into the striatum as a control for the potential
spread of drugs (Figure 6C) did not produce significant
changes of audible and ultrasonic vocalizations in naïve
rats (n = 4, P > 0.05, paired t-test; data not shown).
Discussion
This study determined the effects of a non-opioid neu-
ropeptide (CGRP) in the amygdala, a brain area that has
emerged as an important neural substrate for the emo-
tional-affective component of pain [14,15]. The results
show for the first time that CGRP in the amygdala
(CeLC) of normal animals increases nocifensive and
affective behaviors by increasing synaptic transmission
and neuronal excitability. Synaptic facilitation results
from a postsynaptic mechanism that involves PKA and
NMDA receptors. The key findings are as follows: (1)
Exogenous CGRP facilitated synaptic transmission at the
PB-CeLC synapse that provides nociceptive information
to the CeLC from the parabrachial area as part of the
spino-parabrachio-amygdaloid pain pathway [18-20]. (2)
Analysis of miniature EPSCs and paired-pulse facilita-
tion indicates a post- rather than presynaptic action of
CGRP on CeLC neurons. (3) CGRP also increased neu-
ronal excitability of CeLC neurons, suggesting a direct
cellular effect. (4) The effects of CGRP were largely
blocked by a PKA, but not PKC, inhibitor and by an
NMDA receptor antagonist. (5) Exogenous application
of CGRP into the CeLC increased vocalizations and
spinal reflex responses of normal naïve animals. (6) A
PKA, but not PKC, inhibitor reversed CGRP-induced
behavioral changes. (7) Electrophysiological and beha-
vioral effects of CGRP were antagonized by CGRP8-37.
The significance of these findings is that increasing
CGRP in the amygdala can produce or facilitate pain-
like behaviors in normal animals and these behavioral
effects correlate with increased neuronal activity. Pain
arising from altered brain functions in the absence of
tissue injury represents an important concept that may
apply to so-called functional pain as well as pain states
induced by trigger mechanisms such as in migraine.
Central CGRP actions are thought to play a key role in
migraine pathophysiology [2,55,56]. Other primary head-
aches and disease states such as temporomandibular dis-
orders have been associated with elevated CGRP levels
[55].
Particularly high levels of CGRP [4,10-13] and CGRP
receptors [1,4,8,9] are found in the amygdala, a key
player in affective states and disorders [57-60]. The
amygdala is also involved in emotional-affective aspects
of pain and in pain modulation [14,15]. Previous studies
from our lab [22,26,29-31,34,61] and others [25,32,35]
showed that increased amygdala activity in models of
inflammatory and neuropathic pain correlated with
increased pain behavior. It is conceivable that primarily
non-pain-related activity changes in this brain area
could affect pain responses and pain modulation. Affec-
tive disorders such as anxiety and depression modify
activity in the amygdala [57,59,60] and are highly corre-
lated with pain intensity and duration [62]. The present
study demonstrates directly that increased amygdala
activity in the absence of tissue injury or pain can
exacerbate physiological pain responses such as withdra-
wal reflexes and vocalizations to “physiological” noxious
stimuli (brief compression of peripheral tissue). This
could be an important mechanism by which emotional
disturbances gain access to pain modulation.
Pain-related changes in the CeLC include enhanced
synaptic transmission and neuronal excitability through
a mechanism that is centered on PKA, but not PKC,
activation [34]. PKA increases synaptic transmission in
the nociceptive parabrachio-amygdaloid pathway
through phosphorylation of NMDA receptors [26].
Mechanisms of pain-related PKA activation in the CeLC
are not entirely clear but our previous studies suggest
that CGRP1 [22] and CRF1 [30] receptors could be
upstream of PKA activation. Here we provide direct evi-
dence that the facilitatory effects of CGRP in the CeLC
i n v o l v eP K A ,b u tn o tP K C ,a n dN M D Ar e c e p t o r s .A
PKA, but not PKC, inhibitor reversed the electrophysio-
logical and behavioral effects of CGRP, and in the pre-
sence of an NMDA receptor antagonist CGRP had no
effect. The reversibility of the effects of a PKA inhibitor,
the persistence of facilitation in the presence of a PKC
inhibitor, and the prevention of facilitation by pre-treat-
ment with an NMDA receptor antagonist argue against
de-sensitization of CGRP effects but support the invol-
vement of PKA. In contrast, CGRP actions in the spinal
cord involve both PKA and PKC [40] and modulate
NMDA and AMPA receptor function [38,39]. Both PKA
and PKC contribute to pain-related phosphorylation of
NMDA receptors in the spinal cord [63,64] whereas
only PKA is involved in the amygdala [26,34]. It remains
to be determined if this discrepancy suggests different
mechanisms of CGRP action at different levels of the
pain neuraxis.
Han et al. Molecular Pain 2010, 6:10
http://www.molecularpain.com/content/6/1/10
Page 10 of 14Interestingly, the kinetics of control and CGRP-evoked
AP5-sensitive synaptic responses were largely similar,
whereas NMDA receptors typically mediate slow EPSCs
of longer duration [for recent review see [65]]. Further,
AP5-sensitive EPSCs were recorded at a holding poten-
tial of -60 mV, where NMDA receptor channels would
be expected to be blocked by magnesium. The data can
be explained by the effects of receptor phosphorylation,
which has been shown to relieve the magnesium block
of NMDA receptors, rendering the channel functional
even at -60 mV [66]. NMDA receptor phosphorylation
by PKA or PKC also accelerates the rise and decay
times of the ion channel [67,68], which would explain
the absence of apparent differences in kinetics in the
present study [for discussion see [34]].
The precise mechanism of action of CGRP is not fully
understood, in part because of the complexity of the
CGRP receptor(s). Functional CGRP1 receptors are
formed by a heterodimeric complex of the calcitonin
receptor-like receptor (CRLR) and receptor activity-
modifying protein 1 (RAMP1) [69,70]. Overexpression
of RAMP1 enhanced the pronociceptive effects of CGRP
in the spinal cord [42]. CRLR and RAMP1 are expressed
abundantly in cells of the amygdaloid complex, includ-
ing the central nucleus [9], indicating the presence of
functional CGRP1 receptors. However, CGRP can
Figure 6 Histological verification of drug application sites. Diagrams adapted from [49] show coronal sections through the right hemisphere
at different levels posterior to bregma (-1.88 and -2.12). Next to each diagram is shown in detail the CeA and its subdivisions, the medial (CeM),
lateral (CeL) and latero-capsular (CeLC) part. Each symbol indicates the location of the tip of one microdialysis probe. The boundaries of the
different amygdala nuclei are easily identified under the microscope (see Figure 1 in [30]). Calibration bars for diagrams are 1 mm.
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CGRP1 receptor antagonist (CGRP8-37) did not antago-
nize the facilitatory effects of CGRP on AMPA-evoked
responses of spinal dorsal neurons, which was inter-
preted as evidence for the involvement of a yet
unknown receptor [38]. A CGRP2 receptor has long
been postulated but its constituents have not been iden-
tified. Recently it was suggested that “CGRP2” receptors
may not be a distinct molecular entity but an “amalga-
mation of contributions from a variety of CGRP-acti-
vated receptors” such as those that include RAMP2 or
RAMP3 rather than RAMP1 [71]. In the amygdala, the
BLA contains relatively more RAMP2 than RAMP1
whereas in the CeA RAMP1 expression is highest [9],
consistent with the presence of CGRP1 receptors. Inter-
estingly, anti-nociceptive effects of CGRP have been
reported in the BLA of normal animals, but the synaptic
and cellular actions were not determined [72]. CGRP
receptor composition in different nuclei of the amygdala
could explain the discrepancy with the present study.
Activation of inhibitory projections from the BLA to the
CeLC [54] may also account for inhibitory behavioral
effects of CGRP in the BLA. Finally, mixed effects of
CGRP could result from presynaptic or indirect network
actions in addition to direct cellular effects. The neuro-
nal effects of CGRP in the BLA remain to be
determined.
The consequence of increase in synaptic transmission
and excitability by CGRP was increased nocifensive and
affective responses (withdrawal reflexes and audible and
ultrasonic vocalizations) to brief physiological noxious
stimuli in the absence of tissue injury. Behavioral effects
of amygdala activation suggest that the recorded neu-
rons have access to brainstem centers involved in pain
modulation and generation of vocalizations. CeLC neu-
rons recorded in this study had non-accommodating
action potential firing properties. Non-accommodating
cells, which represent the major neuronal type in the
CeA, were identified previously as medium-size spine-
laden Type A neurons [53,54]. Type A neurons are pep-
tidergic or GABAergic projection neurons with targets
in the brainstem, including PAG, and forebrain
[53,73,74]. Peptidergic (CRF or enkephalin containing)
CeA projection neurons are innervated by CGRP con-
taining terminals [17,46]. Pain-facilitating effects of
CGRP observed in this study could be due to activation
of descending facilitatory brainstem centers or inhibition
of descending inhibition [15,75]
Conclusion
CGRP increases synaptic transmission and excitability in
CeLC neurons in brain slices from untreated naïve ani-
mals, leading to increased spinally and supraspinally
organized pain responses. Synaptic facilitation results
from a postsynaptic mechanism that involves PKA and
NMDA receptors. The study advances not only our
knowledge of CGRP functions in the brain but also our
understanding of pain as a complex condition that can
be triggered and/or exacerbated by neuromodulator
actions in the brain in the absence of tissue injury.
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